Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 15, 2011. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 660,000 Ordinary shares of 25 pence each.
- Purchase Date: November 15, 2011.
- Price Range: Highest price paid was 1,411.5 pence per share; lowest price paid was 1,382 pence per share.
- Treasury Holdings (Settled): 519,202,927 shares (9.32% of total issued share capital).
- Treasury Holdings (Including Unsettled): 519,862,927 shares (10.29% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,053,593,893 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 660,000 shares, increasing the proportion of shares held in Treasury. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (519,202,927 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights represented by treasury shares (10.29% including unsettled purchases).
- Check the remaining authorized share buyback limit under the May 5, 2011 shareholder resolution.
- Review the settlement status of the 660,000 shares purchased on November 15, 2011.